- Home
- PBI vs BCRX Comparison
PBI vs BCRX Comparison
Compare PBI & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBI
- BCRX
- Stock Information
- Founded
- PBI 1920
- BCRX 1986
- Country
- PBI United States
- BCRX United States
- Employees
- PBI N/A
- BCRX N/A
- Industry
- PBI Office Equipment/Supplies/Services
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBI Miscellaneous
- BCRX Health Care
- Exchange
- PBI Nasdaq
- BCRX Nasdaq
- Market Cap
- PBI 1.9B
- BCRX 1.7B
- IPO Year
- PBI N/A
- BCRX 1994
- Fundamental
- Price
- PBI $9.04
- BCRX $7.25
- Analyst Decision
- PBI
- BCRX Buy
- Analyst Count
- PBI 0
- BCRX 6
- Target Price
- PBI N/A
- BCRX $15.67
- AVG Volume (30 Days)
- PBI 2.1M
- BCRX 3.2M
- Earning Date
- PBI 05-01-2025
- BCRX 05-05-2025
- Dividend Yield
- PBI 2.65%
- BCRX N/A
- EPS Growth
- PBI N/A
- BCRX N/A
- EPS
- PBI N/A
- BCRX N/A
- Revenue
- PBI $2,026,598,000.00
- BCRX $450,712,000.00
- Revenue This Year
- PBI N/A
- BCRX $27.66
- Revenue Next Year
- PBI $0.45
- BCRX $13.59
- P/E Ratio
- PBI N/A
- BCRX N/A
- Revenue Growth
- PBI N/A
- BCRX 36.00
- 52 Week Low
- PBI $3.90
- BCRX $4.03
- 52 Week High
- PBI $11.01
- BCRX $9.50
- Technical
- Relative Strength Index (RSI)
- PBI 40.33
- BCRX 34.85
- Support Level
- PBI $9.40
- BCRX $7.44
- Resistance Level
- PBI $9.79
- BCRX $7.93
- Average True Range (ATR)
- PBI 0.33
- BCRX 0.25
- MACD
- PBI -0.07
- BCRX -0.02
- Stochastic Oscillator
- PBI 19.68
- BCRX 3.33
About PBI Pitney Bowes Inc.
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world - including more than 90 percent of the Fortune 500. Small businesses to large enterprises, and government entities rely on Pitney Bowes to reduce the complexity of sending mail and parcels.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.